title: 1,25-dihydroxyvitamin D(3) regulation of fibroblast growth factor-23 expression in bone cells: evidence for primary and secondary mechanisms modulated by leptin and interleukin-6.
abstract: Fibroblast growth factor-23 (FGF23) is a circulating hormone that acts to correct hyperphosphatemic states by inhibiting renal phosphate reabsorption and to prevent hypervitaminosis D by feedback repressing 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) biosynthesis. FGF23 gene expression in the osteoblast/osteocyte is induced by the nuclear vitamin D receptor (VDR) bound to 1,25(OH)2D3, but cycloheximide sensitivity of this induction suggests that it may occur largely via secondary mechanisms requiring cooperating transcription factors. We therefore sought to identify 1,25(OH)2D3-regulated transcription factors that might impact FGF23 expression. Although neither leptin nor interleukin-6 (IL-6) alone affects FGF23 expression, leptin treatment was found to potentiate 1,25(OH)2D3 upregulation of FGF23 in UMR-106 cells, whereas IL-6 treatment blunted this upregulation. Genomic analyses revealed conserved binding sites for STATs (signal transduction mediators of leptin and IL-6 action) along with transcription factor ETS1 in human and other mammalian FGF23 genes. Further, STAT3, STAT1, ETS1, and VDR mRNAs were induced in a dose-dependent manner by 1,25(OH)2D3 in UMR-106 cells. Bioinformatic analysis identified nine potential VDREs in a genomic interval containing human FGF23. Six of the putative VDREs were capable of mediating direct transcriptional activation of a heterologous reporter gene when bound by a 1,25(OH)2D3-liganded VDR complex. A model is proposed wherein 1,25(OH)2D3 upregulates FGF23 production directly via multiple VDREs and indirectly via induction of STAT3, ETS1, and VDR transcription factors that are then activated via cell surface and intracellular signaling to cooperate in the induction of FGF23 through DNA looping and generation of euchromatin architecture.
authors.affiliation: School of Mathematical and Natural Sciences, Arizona State University, Phoenix, AZ 85306, USA.
authors.forename: Rimpi K
authors.initials: RK
authors.lastname: Saini
authors.forename: Ichiro
authors.initials: I
authors.lastname: Kaneko
authors.forename: Peter W
authors.initials: PW
authors.lastname: Jurutka
authors.forename: Ryan
authors.initials: R
authors.lastname: Forster
authors.forename: Antony
authors.initials: A
authors.lastname: Hsieh
authors.forename: Jui-Cheng
authors.initials: JC
authors.lastname: Hsieh
authors.forename: Mark R
authors.initials: MR
authors.lastname: Haussler
authors.forename: G Kerr
authors.initials: GK
authors.lastname: Whitfield
mesh_terms: D000818:Animals; D001859:Bone Neoplasms / Q000378:metabolism / Q000473:pathology; D001842:Bone and Bones / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D019556:COS Cells; D002117:Calcitriol / Q000378:metabolism / Q000494:pharmacology*; D002460:Cell Line; D045744:Cell Line, Tumor; D002522:Chlorocebus aethiops; D000089703:Fibroblast Growth Factor-23; D005346:Fibroblast Growth Factors / Q000235:genetics / Q000378:metabolism*; D005786:Gene Expression Regulation / Q000187:drug effects; D057809:HEK293 Cells; D006801:Humans; D015850:Interleukin-6 / Q000378:metabolism / Q000494:pharmacology*; D020738:Leptin / Q000378:metabolism / Q000494:pharmacology*; D023421:Models, Animal; D012516:Osteosarcoma / Q000378:metabolism / Q000473:pathology; D051381:Rats; D018167:Receptors, Calcitriol / Q000378:metabolism; D050791:STAT Transcription Factors / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects*
chemical_list: C000717427:FGF23 protein, human; D015850:Interleukin-6; D020738:Leptin; D018167:Receptors, Calcitriol; D050791:STAT Transcription Factors; D005346:Fibroblast Growth Factors; D000089703:Fibroblast Growth Factor-23; D002117:Calcitriol